FINANCIAL STATEMENTS ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2007 133 NOTES TO THE FINANCIAL STATEMENTS CONTINUED 10 INTANGIBLE ASSETS Product, marketing and Software distribution Other development rights intangibles costs Total $m $m $m $m Cost At 1 January 2005 3,202 477 596 4,275 Additions separately acquired 43 57 76 176 Exchange adjustments 442 31 23 496 At 31 December 2005 2,803 503 649 3,955 Additions through business combinations 1,260 281 1,541 Additions separately acquired 413 51 121 585 Disposals 675 4 679 Exchange adjustments 372 79 16 467 At 31 December 2006 4,173 910 786 5,869 Additions through business combinations 6,946 1,477 8,423 Additions separately acquired 299 33 178 510 Disposals 52 82 134 Exchange adjustments 183 47 12 242 At 31 December 2007 11,549 2,385 976 14,910 Amortisation and impairment losses At 1 January 2005 1,507 335 372 2,214 Amortisation for year 214 19 39 272 Exchange adjustments 288 3 5 290 At 31 December 2005 1,433 357 406 2,196 Amortisation for year 250 25 50 325 Disposals 14 4 18 Impairment 17 17 Exchange adjustments 190 48 4 242 At 31 December 2006 1,859 443 460 2,762 Amortisation for year 364 112 78 554 Disposals 52 81 133 Impairment 98 22 120 Exchange adjustments 104 32 4 140 At 31 December 2007 2,373 528 542 3,443 Net book value At 31 December 2005 1,370 146 243 1,759 At 31 December 2006 2,314 467 326 3,107 At 31 December 2007 9,176 1,857 434 11,467 Amortisation and impairment charges Amortisation charges are recorded in selling, general and administrative costs and research and development costs in the income statement.
The impairment in 2007 was in relation to the termination of a product in development acquired with MedImmune and four collaboration agreements.
The impairment in 2006 was in relation to the termination of NXY-059 and a collaboration agreement.
These costs were included in research and development in the income statement in both years.
